Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by serendipidyon Jan 04, 2019 1:20pm

178 Views

Post# 29187160

Fickle and Fundametals...

The basic fundamentals of this company have not changed since inception. Im a large, long term investor, have no intention of selling one share for less than 2.00, i dont care how long it takes. Im amused how fickle, and ignorant- not rude- of no knowledge, alot of investors are on here. When saltzman sells theres panic, tho a clear stipulation of the contract, among other things. We have 2 worlwide patents, we will be bought out by a major pharma company down the road, fda approval will be granted, and all the blind studies are amazing..Due dilligence people.....

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale